| Dr William Taylor Hill Jones, MD | |
|
5 Crowningway Dr, Asheville, NC 28804-3707 | |
| (828) 254-9264 | |
| Not Available |
| Full Name | Dr William Taylor Hill Jones |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 33 Years |
| Location | 5 Crowningway Dr, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598876229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0096-00191 (North Carolina) | Secondary |
| 207L00000X | Anesthesiology | ME68837 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| Spartanburg Medical Center | Spartanburg, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mission Health Community Multispecialty Providers Llc | 9537468574 | 577 |
| Spartanburg Medical Center | 3072425297 | 843 |
| Drs. Ellis, Rojas, Ross And Debs, Inc. | 4587563408 | 77 |
News Archive
Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps - a phenomenon known as contractility.
Even the mildest form of a traumatic brain injury, better known as a concussion, can deal permanent, irreparable damage. Now, an interdisciplinary team of researchers at the University of Pennsylvania is using mathematical modeling to better understand the mechanisms at play in this kind of injury, with an eye toward protecting the brain from its long-term consequences.
› Verified 9 days ago
| Entity Name | Providence Anesthesiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396739884 PECOS PAC ID: 3971566761 Enrollment ID: O20041111000930 |
News Archive
Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps - a phenomenon known as contractility.
Even the mildest form of a traumatic brain injury, better known as a concussion, can deal permanent, irreparable damage. Now, an interdisciplinary team of researchers at the University of Pennsylvania is using mathematical modeling to better understand the mechanisms at play in this kind of injury, with an eye toward protecting the brain from its long-term consequences.
› Verified 9 days ago
| Entity Name | Medstream Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649616160 PECOS PAC ID: 7416198049 Enrollment ID: O20140304001209 |
News Archive
Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps - a phenomenon known as contractility.
Even the mildest form of a traumatic brain injury, better known as a concussion, can deal permanent, irreparable damage. Now, an interdisciplinary team of researchers at the University of Pennsylvania is using mathematical modeling to better understand the mechanisms at play in this kind of injury, with an eye toward protecting the brain from its long-term consequences.
› Verified 9 days ago
| Entity Name | Mission Health Community Multispecialty Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457719130 PECOS PAC ID: 9537468574 Enrollment ID: O20160426001883 |
News Archive
Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps - a phenomenon known as contractility.
Even the mildest form of a traumatic brain injury, better known as a concussion, can deal permanent, irreparable damage. Now, an interdisciplinary team of researchers at the University of Pennsylvania is using mathematical modeling to better understand the mechanisms at play in this kind of injury, with an eye toward protecting the brain from its long-term consequences.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Taylor Hill Jones, MD Po Box 2295, Asheville, NC 28802-2295 Ph: (828) 398-5244 | Dr William Taylor Hill Jones, MD 5 Crowningway Dr, Asheville, NC 28804-3707 Ph: (828) 254-9264 |
News Archive
Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013.
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps - a phenomenon known as contractility.
Even the mildest form of a traumatic brain injury, better known as a concussion, can deal permanent, irreparable damage. Now, an interdisciplinary team of researchers at the University of Pennsylvania is using mathematical modeling to better understand the mechanisms at play in this kind of injury, with an eye toward protecting the brain from its long-term consequences.
› Verified 9 days ago
Thomas Broderick Mulford, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 76 Peachtree Rd, Suite 300, Asheville, NC 28803 Phone: 828-274-3477 Fax: 828-274-7407 | |
Everett L Perry, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 76 Peachtree Rd, Suite 300, Asheville, NC 28803 Phone: 828-254-1969 Fax: 828-254-4611 | |
Guy Cavaliere, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 76 Peachtree Rd Ste 300, Asheville, NC 28803 Phone: 828-398-0465 | |
Cecelia Caldwell, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 11 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-213-1740 Fax: 828-213-1742 | |
Steven David Roos, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 76 Peachtree Rd, Suite 300, Asheville, NC 28803 Phone: 828-254-1969 Fax: 828-254-4611 | |
Stephen Don Rathburn, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1100 Tunnel Rd, Asheville, NC 28805 Phone: 828-298-7911 | |
Paul J Harris, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 76 Peachtree Road, Suite 300, Asheville, NC 28803 Phone: 828-274-3477 Fax: 828-274-7407 |